DINGO Study Explores Gynecomastia Preferences in Prostate Cancer
Summary
The Determining INdividual Preferences for Gynecomastia Avoidance (DINGO) study is a qualitative research project examining how men with prostate cancer and high-risk biochemical recurrence perceive the risk of breast-related side effects, including gynecomastia, from cancer treatment. The study uses semi-structured interviews as its intervention method and focuses on understanding patient preferences regarding treatment side effect management. This registry entry documents a planned clinical study with no immediate regulatory or compliance implications.
“This study aims to explore the perceptions of men with prostate cancer (PCa) and high-risk biochemical recurrence (BCR) regarding the risk of breast-related side effects, including gynaecomastia, from treatment.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This registry entry documents the DINGO clinical study, which aims to explore patient preferences regarding gynecomastia risk from prostate cancer treatment. The study focuses on men with prostate cancer and high-risk biochemical recurrence, using semi-structured interviews as the data collection method. The conditions studied include Adenocarcinoma of the prostate. This is an informational entry describing a planned qualitative research project on ClinicalTrials.gov.
Healthcare researchers, oncology providers, and patient advocates may find this study relevant for understanding how prostate cancer patients weigh treatment side effects against therapeutic benefits. The study's findings could inform shared decision-making discussions about treatment options that carry gynecomastia risk. This registry entry does not create any compliance obligations for healthcare providers or institutions.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Determining INdividual Preferences for Gynecomastia avOidance (DINGO) - Stage 1
N/A NCT07552922 Kind: NA Apr 27, 2026
Abstract
This study aims to explore the perceptions of men with prostate cancer (PCa) and high-risk biochemical recurrence (BCR) regarding the risk of breast-related side effects, including gynaecomastia, from treatment.
Conditions: Prostate Cancer (Adenocarcinoma)
Interventions: Semi-structured Interview
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.